Forest Laboratories Inc. have announced filing patent infringement lawsuits against Teva, Barr and others seeking to sell generic versions of Namenda, a treatment for Alzheimer’s disease.
Forest, filed their suit in the U.S. District Court in Delaware, naming Israel- based Teva Pharmaceutical Industries Ltd, Barr Pharmaceuticals Inc and India’s Lupin Ltd as defendents.
With annual sales of around 800 million dollars a year, Namenda is a major product for Forest.
The Namenda patent is due to expire in April 2010, but the patentee has applied for an extension until September 2013.
